Readers of The American Journal of Sports Medicine with an interest in biologic augmentation of healing have seen a wide variety of articles published herein reporting the results of in vitro, animal, and clinical studies evaluating a plethora of various ''orthobiologics.'' The tremendous potential for these approaches to improve tissue healing and regeneration is evident. However, the principal limitation that arises when assessing these studies is the heterogeneity among different formulations. For example, cells derived from various sources including bone marrow, adipose tissue, amnion, placenta, and umbilical cord blood are being investigated as readily available stem cell sources. In the near future, we may be able to use gene therapy techniques to transform a mature, differentiated cell into a cell that is tantamount to an embryonic stem cell. Blood-based formulations in current use or in development include different types of platelet-rich plasma (PRP), autologous conditioned serum, and autologous protein solution as well as approaches that concentrate the protease inhibitor alpha-2 macroglobulin. Further heterogeneity is introduced by the use of allogenic tissues and cells.
It goes without saying that these diverse cell types and blood-based methods will exhibit different biologic activities at the cellular and molecular levels. The tremendous variability in biologic therapies makes clear the need to rigorously characterize the composition and bioactivity of these materials. A critical first step toward this goal is to establish minimum reporting standards for studies that report on biologic therapies. As such, efforts are underway to develop more detailed and refined methods to characterize and classify orthobiologics. The simple classification systems used to date, such as leukocyte-rich versus leukocyte-poor for PRP, are grossly inadequate. Similarly, the standard criteria set forth by the International Society for Cellular Therapy to define mesenchymal stromal cells do not begin to capture the complexity in cell types and biologic activities. As we learn more about the underlying cellular and molecular mechanisms of progenitor cells, it is clear that more refined and detailed methods to characterize these formulations are required. Ultimately, genomic, proteomic, and metabolomic approaches should be used to begin to clarify the composition and biologic activity of these materials. Recent studies have highlighted the inconsistency in the nomenclature used to describe cell therapies and the frequent disconnect between the nomenclature used and the actual cell formulation. 1 Furthermore, expedited regulatory approval pathways from the US Food and Drug Administration further make clear the need for rigorous methods to test and characterize orthobiologics.
Investigators in this field have recognized the need for standardized algorithms to guide others in reporting salient characteristics of various orthobiologic therapy formulations. The purpose of such algorithms is to improve standardization and transparency in studies reporting on PRP, cell therapy, and other emerging treatment modalities. A growing number of acronyms have been proposed for the classification of biologic therapies. These various algorithms record comprehensive information about the material injected, including details related to the source, dose, composition, biologic activity, potency, purity, and preparation protocol for either PRP or a cell therapy formulation. Other important categories of information incorporated in these algorithms include details about the patient and the underlying abnormality being treated. Some also include details related to the method of delivery of the treatment, the posttreatment protocol, and outcome assessments. These classification schemes should help to bring some standardization to the complex and evolving field of biologic therapies. Table 1 lists some of these recently described algorithms.
I believe that clinicians, the industry, and authors of both laboratory and clinical studies should begin to use these tools and algorithms when communicating the results of biologic therapy investigations. The challenge is identifying the optimal system to recommend at this time. I would recommend the use of ''minimum information for studies evaluating biologics in orthopaedics'' (MIBO). 2 In choosing an algorithm to use, it should be recognized that most of the current classification systems are designed for autologous point-of-care products such as bone marrow or adipose cells and PRP. The ideal system will need to accommodate new products that may be available in the near future. For example, as more ''manufactured'' products become available, we will need algorithms that include information about the manufacturing process and preservation of orthobiologic therapies. Further complexity is added by the emerging development of gene-modified cells and products that use extracellular vesicles (exosomes) derived from stem cells. Our classification systems need to be able to adapt to new and emerging paradigms and treatment No matter what specific algorithm or system is used to characterize orthobiologics, we need to develop assays and analytical methods that are practical, readily available, and cost-effective. Measurements of the composition, bioactivity, purity, and potency of biologic treatments can become very complex and impractical to perform on a regular basis outside of large institutions with strong laboratory support. Ultimately, we need to identify a small practical set of ''sentinel markers'' of the critical quality attributes of these materials. Ideally, such analytical testing methods can be performed at the point of care. As with any assay, specificity, sensitivity, accuracy, and reproducibility will need to be established.
Finally, once we identify the optimal method to characterize orthobiologics, the other side of the equation is to identify the biologic targets that we want to treat for different tissues and abnormalities. Only once we do this can we match the appropriate orthobiologic with the specific condition being treated. Detailed characterization of these biologic formulations is only useful if we can then use the information to choose the appropriate treatment for the patient. Clearly, one size does not fit all. Algorithms such as MIBO will eventually allow the classification of various biologic formulations into categories that will facilitate clinical and translational research. An important reason for the variability in the outcomes reported for various orthobiologics is the fact that the same cell therapy or PRP formulations have been used to treat a myriad of very different tissues and abnormalities. Further basic laboratory and translational research to define the underlying cellular and molecular mechanisms of musculoskeletal disease will help to guide a much more refined approach to the use of orthobiologics, which I believe will allow us to begin to realize the tremendous potential of biologic therapies. Finally, the adoption of minimum reporting standards that facilitate the characterization of biologic therapies will bring us closer to a personalized medicine approach to therapy for our patients in which the goal is to provide the right patient with the right drug at the right dose at the right time. 
